基于PD-L1联合阳性评分与肿瘤细胞评分的CheckMate 274随机试验中高危肌层浸润性尿路上皮癌患者无病生存分析
CheckMate 274试验显示,高危肌层浸润性尿路上皮癌根治术后,纳武利尤单抗辅助治疗较安慰剂改善无病生存(DFS)。本分析按联合阳性评分(CPS)和肿瘤细胞(TC)评分评估DFS,629例可评估患者中CPS≥1者557例(89%),TC≥1%者249例(40%);TC<1%者中81%为CPS≥1。纳武利尤单抗在TC≥1%、CPS≥1及TC<1%且CPS≥1患者中均改善DFS。
要点
- TC<1%患者中81%为CPS≥1,CPS≥1者多于TC≥1%者。
- TC≥1%患者纳武利尤单抗较安慰剂改善DFS(HR 0.50,95%CI 0.35-0.71)。
- TC<1%且CPS≥1患者纳武利尤单抗较安慰剂改善DFS(HR 0.73,95%CI 0.54-0.99)。
核心结论
- CPS≥1患者多于TC≥1%患者,且多数TC<1%患者为CPS≥1。
- CPS≥1患者接受纳武利尤单抗后DFS改善。
- 结果可能部分解释TC<1%且CPS≥1患者仍可从辅助纳武利尤单抗获益的机制。
研究设计与样本
- CheckMate 274随机试验,709例患者1:1随机接受纳武利尤单抗240 mg或安慰剂每2周静脉给药,辅助治疗≤1年。
- CPS从既往染色切片回顾性确定,分析同时具有可量化CPS和TC的肿瘤样本。
主要发现
- 629例可评估CPS和TC患者中,CPS≥1者557例(89%),CPS<1者72例(11%)。
- TC≥1%者249例(40%),TC<1%者380例(60%);TC<1%者中81%(n=309)为CPS≥1。
- TC≥1%患者纳武利尤单抗较安慰剂改善DFS(HR 0.50,95%CI 0.35-0.71)。
- CPS≥1患者纳武利尤单抗较安慰剂改善DFS(HR 0.62,95%CI 0.49-0.78)。
- TC<1%且CPS≥1患者纳武利尤单抗较安慰剂改善DFS(HR 0.73,95%CI 0.54-0.99)。
关键数值与推荐
- 主要终点为意向治疗人群和肿瘤PD-L1表达≥1%(TC评分)患者的DFS。
- CPS基于肿瘤和免疫细胞PD-L1表达,本分析回顾性确定。
临床怎么用
- 原文未据此给出推荐。
局限性
- CPS为回顾性确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The CheckMate 274 trial demonstrated improved disease-free survival (DFS) with adjuvant nivolumab versus placebo in patients with muscle-invasive urothelial carcinoma at high risk of recurrence after radical surgery in both the intent-to-treat population and the subset with tumor programmed death ligand 1 (PD-L1) expression ≥1%. OBJECTIVE: To analyze DFS by combined positive score (CPS), which is based on PD-L1 expression in both tumor and immune cells. DESIGN, SETTING, AND PARTICIPANTS: We randomized a total of 709 patients 1:1 to nivolumab 240 mg or placebo every 2 wk intravenously for ≤1 yr of adjuvant treatment. INTERVENTION: Nivolumab 240 mg. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary endpoints were DFS in the intent-to-treat population and patients with tumor PD-L1 expression ≥1% using the tumor cell (TC) score. CPS was determined retrospectively from previously stained slides. Tumor samples with both quantifiable CPS and TC were analyzed. RESULTS AND LIMITATIONS: Of 629 patients evaluable for CPS and TC, 557 (89%) had CPS ≥1, 72 (11%) had CPS <1, 249 (40%) had TC ≥1%, and 380 (60%) had TC <1%. Among patients with TC <1%, 81% (n = 309) had CPS ≥1. DFS was improved with nivolumab versus placebo for patients with TC ≥1% (hazard ratio [HR] 0.50, 95% confidence interval [CI] 0.35-0.71), those with CPS ≥1 (HR 0.62, 95% CI 0.49-0.78), and patients with both TC <1% and CPS ≥1 (HR 0.73, 95% CI 0.54-0.99). CONCLUSION: More patients had CPS ≥1 than TC ≥1%, and most patients who had TC <1% had CPS ≥1. In addition, patients with CPS ≥1 experienced improved DFS with nivolumab. These results may, in part, explain the mechanisms underlying a benefit with adjuvant nivolumab even in patients who had both TC <1% and CPS ≥1. PATIENT SUMMARY: We studied survival time without cancer recurrence (disease-free survival; DFS) for patients treated with nivolumab versus placebo after surgery to remove the bladder or components of the urinary tract for bladder cancer in the CheckMate 274 trial. We assessed the impact of levels of the protein PD-L1 expressed either on tumor cells (tumor cell score; TC) or on both tumor cells and immune cells surrounding the tumor (combined positive score; CPS). DFS was impoved with nivolumab versus placebo for patients with TC ≥1%, CPS ≥1, and for patients with both TC <1% and CPS ≥1. This analysis may help physicians understand which patients would benefit most from treatment with nivolumab.
引用
- Galsky MD, Bajorin DF, Witjes JA, et al. Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score. Eur Urol. 2023. PMID: 36868932. doi:10.1016/j.eururo.2023.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。